Humoral hypercalcemic factor antagonists with modification at position 13 . . .
US5087562A · kind A · utility
13Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 25, 1990 |
| Grant date | Feb 11, 1992 |
| Priority date | — |
| Expiry date | Apr 25, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/29
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.